DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD) MARKET ANALYSIS

Disease-Modifying Antirheumatic Drug (DMARD) Market, by Drug Type (Synthetic (sDMARD), (Conventional synthetic (csDMARDs), (Methotrexate, Sulfasalazine, Leflunomide, Hydroxychloroquine and Gold Salts), Targeted synthetic DMARDs (tsDMARDs), Biological DMARDs (bDMARD), (Original DMARDs (boDMARDs), Biosimilar DMARDs (bsDMARDs), (Primary, Secondary and Tertiary) and Others), by Route of Administration (Oral, Parenteral and Others), by Indication (Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Systemic Lupus Erythematosus and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Aug 2022
Code : CMI5185
Pages :156
Formats :
Excel and PDF
Industry : Pharmaceutical

Disease-Modifying Antirheumatic Drug (DMARD) MarketSize and Trends

The global disease-modifying antirheumatic drug (DMARD) market is estimated to be valued at US$ 20,671.1 million in 2022 and is expected to exhibit a CAGR of 3.5% during the forecast period (2022-2030).

Figure 1.Global Disease-Modifying Antirheumatic Drug (DMARD) Market Share (%) in Terms of Value, By Drug Type, 2022

Increasing prevalence of rheumatoid arthritis disease is expected to drive the market growth during the forecast period.

Increasing prevalence of rheumatoid arthritis disease which is expected to drive the global disease-modifying antirheumatic drug (DMARD) market growth over the forecast period. For instance, according to data published by National Center for Biotechnology Information in June 2022, stated that the annual incidence of RA (Rheumatoid Arthritis) in the U.S. and other western nations of northern Europe is about 40 per 100,000 persons.